Edward Nirenberg on Nostr: Clesrovimab has been modified with the YTE mutations to enhance its half-life to 44 ...
Published at
2024-10-23 20:57:00Event JSON
{
"id": "3dcd0a7faf635b3916b41df109874fb50a51e47a74aac874c9efad1f4f36986b",
"pubkey": "c67b38e4c5023e985f04ae7ab6a6669cf463220e1b9ed54b897d1957004603a4",
"created_at": 1729717020,
"kind": 1,
"tags": [
[
"e",
"1d72a6d8a391f8cde4329fdb9084ae77607c6a9f5b6d206a65cc2fe0a2f14201",
"wss://relay.mostr.pub",
"reply"
],
[
"proxy",
"https://med-mastodon.com/users/enirenberg/statuses/113358734660216875",
"activitypub"
]
],
"content": "Clesrovimab has been modified with the YTE mutations to enhance its half-life to 44 days. Clesrovimab has been assessed in a Phase 2b/3 study compared with placebo (IMO it should have been compared with palivizumab).\n\nhttps://cdn.masto.host/medmastodoncom/media_attachments/files/113/358/734/538/311/662/original/6bd101ba5702691f.png\n\nhttps://cdn.masto.host/medmastodoncom/media_attachments/files/113/358/734/529/970/802/original/91d1f066b5548ff3.png\n\nhttps://cdn.masto.host/medmastodoncom/media_attachments/files/113/358/734/443/356/908/original/1a564f0b8ff2f2f4.png\n\nhttps://cdn.masto.host/medmastodoncom/media_attachments/files/113/358/734/479/136/222/original/8ea6ecf26a80e841.png",
"sig": "ba2221de4d7247252658c3bd3aef1da35bf5ed0b71ed8aafe0a9541bbcf514d1875995293f72eca795d9ad4367b75b9a12e1c911ed16b46e508526ddf4796b79"
}
